Upgrade to SI Premium - Free Trial

Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)

June 13, 2024 7:59 AM
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $157.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles